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Aims. This study determined the eﬀects ofasingledoseofbevacizumab,an antiangiogenicrecombinantmonoclonalantibody that
speciﬁcallytargetsvascularendothelialgrowthfactor(VEGF),onadhesionformationintheratcecalabrasionmodel.Methodology.
Thirty female Wistar albino rats (200–224g) were divided into three groups. All rats underwent laparotomy at which time cecal
wall abrasion and abdominal wall injuries were induced. Group I (control) underwent only the abrasion procedure; Groups II
and III received salineor bevacizumab intraperitoneally, respectively, followingthe abrasion.The rats were killed on postoperative
day 7, and the severity of adhesions was evaluated, together with histopathologicalﬁbrosis parameters and immunohistochemical
staining to identify the VEGF receptor. Results. The mean adhesion severity score in Groups I–III was 2.5 ± 0.52, 2.4 ± 0.69, and
0.7 ± 0.82, respectively; the score in Group III was signiﬁcantly lower than that in Groups I (P<0.001) and II (P<0.001). In the
histopathological evaluation, the mean ﬁbrosis score in Group III was signiﬁcantly lower that the scores in Groups I (P<0.001)
and II (P<0.001).VEGF stainingof the adhesion areas in Group III was signiﬁcantlylower than that in Groups I (P<0.001) and
II (P<0.001). Conclusion. Bevacizumab decreases adhesion formation following laparotomy in rats by blocking VEGF receptor
occupancy.
1.Introduction
Postoperativeadhesion formationisamajorclinicalproblem
inpatientswho undergoabdominalsurgery [1,2].Peritoneal
adhesions are deﬁned as pathological ﬁbrotic bands that
develop between any surfaces in the peritoneal cavity [2].
These adhesions can be induced by infection, inﬂammation,
ischemia, and surgical injury and are the leading cause of
pelvic pain, infertility, and bowel obstruction. The mecha-
nisms underlying the predisposition to form adhesions and
their site speciﬁcity are unknown [2–4]. Intra-abdominal
adhesions are believed to develop as a result of ischemia and
trauma to the serosal surface of bowel or peritoneum [4–
6]. After peritoneal injury, vascular permeability is increased
in vessels supplying the damaged area; this is followed by
an exudation of inﬂammatory cells ultimately leading to
the formation of ﬁbrin matrix, which connects two injured
peritoneal surfaces forming ﬁbrin bands [6, 7].
Following ﬁbrin band formation, ﬁbrinolysis breaks the
bands into smaller molecules as ﬁbrin degradation products
[7, 8]. If the ﬁbrinolysis system is depressed, the adhesions
are not lysed completely and the ﬁbrin bands persist [8]. The
tissue forming the adhesions is a mixture of macrophages,
red blood cells, ﬁbroblasts, nerve ﬁbers, and small vascular
channels ofendothelialcells.Macrophagesplayanimportant
role in this condition as they synthesize and release growth
factor, which is mitogenic, chemotactic, and angiogenic [1,
9].
Angiogenesis, the process of developing new blood
vessels, isafundamentalprocess ininﬂammation and wound
repair. Angiogenesis is turned on or oﬀ by regulatory factors
located in the extracellular matrix, which acts as a reservoir2 Gastroenterology Research and Practice
of factors that can be released after wounding or under other
physiological conditions [10]. Human peritoneal capillaries
and arteriole endothelial cells express vascular endothelial
growth factor (VEGF) and angiogenic factors that regulate
the proteolytic enzymes and their inhibitors.
Since VEGF plays a key role in coagulation, ﬁbrinolytic,
and angiogenic activities, it is considered a critical cytokine
in the development of peritoneal adhesions [1, 10, 11]. We
hypothesized that the angiogenesis inhibitor bevacizumab
can reduce peritoneal adhesions by increasing VEGF levels
a n di n v e s t i g a t e dt h ee ﬀects of bevacizumab on intraperi-
toneal adhesions.
2.Materialsand Methods
2.1. Protocol. This study was conducted in the Experimental
Animal Raising and Research Laboratory of Firat University,
Faculty of Medicine, Elazig, Turkey, after the approval of the
local ethics committee. All experimental manipulations were
in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals.
2.2. Animals. Thirty female Wistar albino rats (11–12 weeks
of age, weighing 200–224g) were acclimatized for 1 week
before the experiments. The animals were kept in individual
cages, housed at constant room temperature, and given
standard rat chow. Only water was provided in the 12h
preceding the experiments.
2.3. Experimental Groups. T h er a t sw e r ed i v i d e dr a n d o m l y
into three groups by block randomization using Random
Allocation Software ver. 1.00. The researchers were blinded
to the treatment, saline, and control groups. In Group
I (control), abrasion only was performed. In Group II,
abrasion was performed and 0.9% NaCl was administered
intraperitoneally. In Group III, abrasion was performed and
2.5mg/kg bevacizumab (Avastin, 25mg/mL, Roche, Basel,
Switzerland) was administered intraperitoneally.
2.4. Experimental Design. All rats were anesthetized with
a combination of 5mg/kg intramuscular xylazine (Bayer,
Istanbul, Turkey) and 30mg/kg ketamine hydrochloride
(Parke-Davis, Istanbul, Turkey). All animals breathed spon-
taneously throughout the procedures. The mid-abdominal
area was shaved and prepared with povidone-iodine as
antiseptic. A 3cm midline incision was made and the cecum
was exteriorized. A 1-2cm2 area of the cecum was brushed
eight to ten times with a gauze bandage, and then a 1cm2
peritoneal injury on the right abdominal wall opposite to
the cecum was also produced by brushing. The abdominal
incision was closed with continuous 3-0 silk sutures. Only
waterwasgiventoalloftheanimalsontheﬁrst postoperative
day; standard rat chow and water were provided on the
succeeding days.
On postoperative day 7, the rats were anesthetized as
previouslydescribedand arepeat laparotomy wasperformed
with a reversed U-shaped incision of the anterior abdominal
Table 1:Deﬁnitionsofthegradesofperitonealadhesionsaccording
to Evans.
Grade Deﬁnitions of severity grades of the peritoneal
adhesions according to Evans model
0N o a d h e s i o n s
1 Thin, avascular, spontaneously separating adhesions
2 Limited vascularization, adhesions separating by
traction
3 Good vascularization,adhesions separating by
dissection
Table 2: Deﬁnitions of the histopathologicalﬁbrosis score.
Grade Deﬁnitions of the histopathologicalﬁbrosis scoring
0 No ﬁbrosis (no ﬁbroblast and/or collagen ﬁber)
1 Slight ﬁbrosis—few ﬁbroblast and/or collagen ﬁbers
2 Median ﬁbrosis (more ﬁbroblast and/or collagen ﬁbers)
3 Severe ﬁbrosis (lots of ﬁbroblasts and/or collagen ﬁbers)
wall, which was retracted caudally to provide maximal ex-
posure,withoutdamaging theareainwhich theabrasionhad
been performed.
2.5. Adhesion Assessment and the Adhesion Severity Score.
Adhesions were assessed between organs and the abdominal
wallandamongtheorgansthemselves.Twosurgeonsblinded
to the study (not members of the surgical team) scored the
adhesions separately, and a consensus score was obtained
for each rat. The type of adhesions was scored according
to the method of Evans et al. [12], in which Grade 0 indi-
cates no adhesions, Grade I indicates adhesions separating
spontaneously, Grade II indicated adhesions separating by
traction, and Grade III indicates adhesions separating with
sharp dissection (Table 1,F i g u r e s1(a)–1(d)).
2.6. Fibrosis Score. The adhesions were excised with the
adhesion surfaces, and the resected adhesion specimens
were ﬁxed in formaldehyde. After dehydration, they were
embedded in paraﬃn. Then, 5mm cross-sections were
prepared, stained with hematoxylin and eosin (H&E), and
evaluated under a light microscope at a magniﬁcation of
×100. The adhesions were categorized as histopathological
Grades 0–III based on the presence and extent of ﬁbrosis
[1, 4–6]. All evaluations were performed by an experienced
pathologist who was blinded to the groups. Grade 0 was
deﬁned as no ﬁbrosis, Grade I as slight ﬁbrosis, Grade II
as intermediate ﬁbrosis, and Grade III as severe ﬁbrosis
(Table 2).
2.7. Immunohistochemical (IHC) Staining Procedure. The
adhesionswere excisedwiththeadhesionsurfaces. Theadhe-
sion tissue was placed in 10% formaldehyde for both VEGF
(NeoMarkers, ready to use; Neomarkers Inc., Fremont, CA,
USA) receptor level measurements and IHC analysis. After
fewhoursinﬁxative,thebiopsyspecimenswereembeddedinGastroenterology Research and Practice 3
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Figure 1: Appearance of peritoneal adhesions in rats. Grade 0 (a), I (b), II (c), and III (d) adhesions.
paraﬃn,and5μmsliceswere cutandplacedonamicroscope
slide. The tissue was stained with IHC stain used to identify
the VEGF receptor. All evaluations were performed by an
experienced pathologist who was blinded to the groups. The
IHC staining severity and density of VEGF antibodies were
evaluated in the areas where the stained cells were found in
the adhesion tissues. The results were evaluated as follows: 0:
no staining (negative), 1 = suspected, 2: mild, 3: moderate,
and 4: strongly positive (Figures 2(a)–2(d))[ 9].
2.8. Primary and Secondary Endpoints. The primary end-
point of this experimental study was the macroscopic
adhesion score, which is the sum of the adhesion severity
grading. The secondary endpoint was the microscopic brosis
grading, extracted from the adhesion model area.
2.9. Statistical Analysis. The data were analyzed using SPSS
17.0 for Windows (SPSS Inc., Chicago, Il, USA). Percentages
were compared with Student’s t-test, and the Pearson Chi-
square test was used for nonparametric values. The P values
given are 2-sided; P<0.05 was considered to be the limit of
signiﬁcance.
3.Results
A total of 30 rats were operated. There was no wound
dehiscence; three animals developed an incision hernia: 2 in
Group II and one in Group III.
3.1. Adhesion Severity Score. Statistical comparison showed
that the adhesion severity score in the bevacizumab group
(Group III) diﬀered signiﬁcantly from the scores in Groups
I( P<0.001) and II (P<0.001), while no diﬀerence
was observed between Groups I and II (P = 0.72). The
adhesion scores of the three groups and statistical analysis
are summarized in Table 3.T h es t a t i s t i c a ld i ﬀerences among
all groups are also shown in Figure 3 .4 Gastroenterology Research and Practice
(a) (b)
(c) (d)
Figure 2: Immunohistochemistry for VEGF. No staining(a), suspected staining (b), moderate staining (c), and strong staining (d).
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Figure 3: The bevacizumab group had a signiﬁcantly lower ad-
hesion grades.
Table 3: Macroscopic adhesion severity grades and mean group
scores.
Groups Adhesion severity score
Grade 0 Grade 1 Grade 2 Grade 3 Mean ± SD
I0 0 5 5 2 . 5 ± 0.52
I I 0145 2 . 4 ± 0.69
I I I5320 0 . 7 ± 0.82
I versus II: P = 0.72; I versus III; P<0.001; II versus III; P<0.001.
3.2. Histopathological Fibrosis Score. The ﬁbrosis score in
Group III was signiﬁcantly less than that in Groups I (P<
0.001) and II (P<0.001), while the ﬁbrosis score did not
diﬀer signiﬁcantly between Groups I and II (P = 0.55). The
ﬁbrosis scores and the statistical analysis are summarized in
Table 4.T h es t a t i s t i c a ld i ﬀerences among all groups are also
shown in Figure 4.Gastroenterology Research and Practice 5
Table 4: Microscopic histopathological ﬁbrosis severity grades and
mean group scores.
Fibrosis score
Groups Grade 0 Grade 1 Grade 2 Grade 3 Mean ± SD
I 0145 2 . 4 ± 0.69
I I 0244 2 . 2 ± 0.78
III 6 3 1 0 0.5 ± 0.70
I versus II: P = 0.55; I versus III; P<0.001; II versus III: P ≤ 0.001.
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Figure 4: The bevacizumab group had a signiﬁcantlylower ﬁbrosis
scores.
3.3. Immunohistochemical Staining for VEGF. The VEGF
staining of the adhesion areas in Group III was signiﬁcantly
lower than that in Groups I (P<0.001) and II (P<0.001),
while no signiﬁcant diﬀerencewas observed betweenGroups
Ia n dI I( P = 0.27). The VEGF staining scores and the
statistical analysis are summarized in Table 5.T h es t a t i s t i c a l
diﬀerences among all groups are also shown in Figure 5.
4.Discussion
Abdominal and pelvic adhesions are a major cause of
morbidity,resulting in abdominal and pelvic pain, infertility,
and small bowel obstruction. They are responsible for 30–
41% of all intestinal obstructions [13]. Furthermore, pelvic
adhesions resulting in mechanical blockage of the fallopian
tubes are an important cause of infertility [14, 15]. Despite
technological advances, postoperative peritoneal adhesions
continue to constitute signiﬁcant problems and remain
a source of frustration for patients who have undergone
laparotomy [16].
Various models have been developed to induce postop-
erative peritoneal adhesions experimentally, including local
peritoneum excision, ischemic damage, the introduction of
foreign objects into the peritoneal cavity, thermal dam-
age, and bacterial contamination [4]. Any manipulation
performed by the hands or surgical instruments during
laparotomy constitutes mechanical trauma, which is the
most frequent cause of postoperative peritoneal adhesions
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Figure 5:The bevacizumabgrouphada signiﬁcantlylowerstaining
with VEGF immunohistochemical stain.
[4, 5]. We used a cecal abrasion model because it mimics the
mechanical trauma that occurs during laparotomy.
Peritoneal adhesions are actually the result of normal
wound healing, and postoperative peritoneal adhesions are
seen most commonly within 7 to 15 days after surgery. Four
similar, previously published studies were performed with
species-speciﬁc antibodies to VEGF; in these studies, the test
period (relaparotomy) was restricted to 7 and 30 days [1, 3,
9]. Our study was performed with a humanized antibody,
in a species where abundant literature suggests a similarity
in eﬀect of bevacizumab in rats and humans. Our follow-up
period was 7 days, and the adhesion maturation process can
be aﬀected by the reabsorbed circulating bevacizumab since
it remains in circulation up to 6 weeks [1].
The search for an eﬀective antiadhesion device has been
continuing for decades. Several methods, materials, and
agents have been assessed for their ability to prevent intra-
abdominal peritoneal adhesions, including various surgical
procedures, minimally invasive and laparoscopic techniques,
pharmacological agents that target ﬁbrin formation, and
liquids, gels, and solids that can form a mechanical barrier
between mesothelial surfaces [3–6].
Many animal and clinical studies have tested a vari-
ety agent to prevent intra-abdominal adhesion formation.
These agents include dextran, honey, resveratrol, hyaluronic
acid corticosteroid, saline, recombinant tissue plasmino-
gen activators, aprotinin, atorvastatin, octreotide, heparin,
nonsteroidal inﬂammatory drugs, tenoxicam, mitomycin,
sildenaﬁl, vitamin E, melatonin, and β-glucan [1, 3–7]. The
intra-abdominal administration of antiadhesive barriers,
such as a bioresorbable membrane consisting of sodium
hyaluronate, polyethylene glycol, ﬁbrin sealant, oxidized
regeneratedcellulose,expandedpolytetraﬂuoroethylene,and
carboxymethylcellulose, may reduce postoperative adhe-
sions, as demonstrated by some animal models and clinical
studies [1, 4–6]. Some of these agents have been shown to
reduce the number and quality of adhesions, but none are6 Gastroenterology Research and Practice
Table 5: The severity of immunohistochemicalstaining with VEGF antibody.
VEGF immunohistochemicalstaining
Groups Negative (=0) Suspected (=1) Mild (=2) Moderate (=3) Strongly (=4) Mean ± SD
I0 0 2 4 4 3 . 2 ± 0.78
II 0 2 2 3 3 2.7 ± 1.16
III 6 3 1 0 0 0.5 ± 0.70
I verus II: P = 0.27; I versus III; P<0.001; II versus III: P<0.001.
universally eﬀective and their modes of action are poorly
understood [8, 17].
This study investigated the eﬀect of bevacizumab, a
monoclonalantibody against VEGF,in preventingperitoneal
adhesions. The adhesions were graded using the method of
Evans et al. [12]. The intensity of peritoneal adhesions was
reduced dramatically in the bevacizumab group compared
to the controls and 0.9% NaCl group (P<0.001).
Intraperitoneal adhesion formation is a complex process
that involves multiple factors, including the proliferation
of blood cells and matrix components and angiogenesis.
Theoretically, angiogenesis should play an important role in
the development of intra-abdominal adhesions because the
extent of early neovascularization correlates with adhesion
formation.
The mesothelial and vascular endothelial cells in the
peritoneal blood vessels, which supply peritoneal adhesions,
express both VEGF and ﬁbroblast growth factor-2 (FGF-2),
indicating a role for these cytokines in mediating peritoneal
angiogenesis during adhesion formation [9].
Human peritoneal capillaries and arteriolar endothelial
cells express VEGF and other angiogenic factors that may
regulate proteolytic enzymes and their inhibitors. VEGF is a
critical cytokine in the development of peritoneal adhesions,
and it has an essential role in the induction of angiogenesis;
it is also an endothelial cell-speciﬁc mitogen [10, 18–20].
VEGF is a potent, angiogenic cytokine that is involved
in the formation of adhesions; perhaps its role is to induce
the development of new blood vessels supplying areas of
tissue damage/injury induced by surgery [21]. It is also
involved directly in tissue restoration, including the early
inﬂammatory responses and wound repair and remodeling
via ﬁbroblast function [22]. The central role of VEGF in
facilitating the deposition of the ﬁbrin-rich matrix necessary
for subsequent cellular migration and proliferation would
seem to make it a key agent in the formation of peritoneal
adhesions [22]. Cahill et al. [23] showed that it is involved
centrally in the early pathogenesis of postoperative adhesion
formation and that mast cells seem to be responsible for the
early surge in peritoneal VEGF levels after an operation.
Bevacizumab is a recombinant humanized monoclonal
antibody that binds all biologically active isoforms of VEGF
andinhibitsbindingofthiscytokinetoitsreceptors:VEGFR-
1and-2[24–27].ItneutralizesthebiologicaleﬀectsofVEGF,
including endothelial cell mitogenesis, vascular permeability
enhancement, and the promotion of angiogenesis. In mouse
models, the administration of anti-VEGF antibodies was
shown to block the growth of human tumor xenografts and
reduce the size and number of metastases [18, 28].
VEGF seems to have important roles in the early
formation of intra-abdominal postoperative adhesions. It is
released into the peritoneal cavity from the injured vascula-
tureafter surgery. Bevacizumabneutralizes VEGF and blocks
its signal transduction through both VEGFR-1 and VEGFR-
2, as demonstrated by the inhibition of VEGF-induced cell
proliferation and the modulation of peritoneal adhesions
by neutralizing antibodies [29, 30]. The role of selective,
antiangiogenic inhibitors in the treatment of neoplastic
processesmaybeexpandedtoincludeantiadhesionstrategies
[29].
In our model, following the administration of beva-
cizumab, VEGF receptor levels and angiogenesis decreased
in the excised adhesion surfaces and ﬁbrin tissue, as shown
in the histopathological examination. The application of
bevacizumab reduced angiogenesis, which may have accom-
panied the reduction in adhesion formation. Bevacizumab
reduced the VEGF receptor count in the injured tissue.
Therefore, bevacizumab lowers the formation of adhesions
by binding and blocking VEGF receptors. This result may
open new horizons for this drug, which is currently pre-
scribed for anticancer purposes, in preventing adhesion
formation following laparotomy in high-risk patients.
We conclude that bevacizumab prevented postoperative
adhesion formation experimentally. However, additional
research and clinical trials are needed to investigate and
validate its long-term eﬀects and to establish a safe protocol
for its use.
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